NEXT BREAKTHROUGH: The Biomedical Innovation Brainstorm
One of the limitations Dr. Hélène Côté recognizes in this field of research is the complexity behind the intaking of these antiretroviral drugs in individuals, where causation is not always clear. If this can be done, she says, on a scale which allows answering of questions with more granularity, she would be able to close in on what antiretroviral drug does what, and figure out a link between the drug and its affects. Welcome back, everyone, to Next Breakthrough, our hub of biomedical innovation brainstorm! My name is Francesca Chen, and I’m very excited to introduce to you all Dr. Hélène Côté. In this episode, Dr. Hélène Côté, a PI and professor in the Department of Pathology and Laboratory Medicine at UBC talks about her team’s research in HIV medication. Our discussion tracks the journey of antiretroviral drugs’ introduction- from initial adverse affects-to now, and current improvements of patients’ lives, to more internal aspects such as mitochondrial toxicity and antiretroviral impacts on mtDNA depletion, the relationship of these drugs to telomere length, how these drugs influence pregnancy and preterm delivery, and much more. Ending off is a reflection on how the fight against HIV has progressed in the past years, current challenges researchers like Dr. Côté and her team face, and anticipated progression in the future. There’s lots of densely packed intriguing insights in our conversation, so let’s dive right in! And as always, please consider following this podcast to increase the size of your biomedical brain. And without further ado, here is Dr. Hélène Côté.
7 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de NEXT BREAKTHROUGH: The Biomedical Innovation Brainstorm!